☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Regeneron
Regeneron Reports the Acceptance of its MAA by the EMA for Linvoseltamab to Treat Multiple Myeloma (MM)
February 5, 2024
Regeneron Reports Positive Results of Odronextamab in P-II (ELM-2) Trial for the Treatment of Follicular Lymphoma
December 12, 2023
Regeneron Reports Two-Year (PULSAR) Trial Results of Eylea HD (aflibercept) for Wet Age-Related Macular Degeneration
October 6, 2023
Regeneron and Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent to Treat Eosinophilic Esophagitis in Chi...
September 26, 2023
Regeneron’s Eylea HD (aflibercept) Receives the US FDA’s Approval for Serious Retinal Disease
August 21, 2023
Regeneron Reports EMA Acceptance of MAA for Odronextamab to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell...
August 18, 2023
Load more...
Back to Home